Belite Bio (BLTE) to offer ADS and warrants
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/6/2026
- Wall St futures rise as Treasury yields cool, oil slips
- Oil slips as Mideast exports, G7 stockpile ease supply concerns
- U.S. 10-year yield climb revives dotcom-era parallels: UBS weighs in
- Goldman flags 2 key market risks if a climb in yields persists
- Intel stock slides as TSMC explores Terafab tie-up, analyst flags share losses
- Citi cuts investment banking analyst program to two years - Bloomberg
- Paramount Skydance to close WBD deal, change ticker to SKYD
- HubSpot to cut 7% of workforce in restructuring plan
- Nasdaq notches record high close as investors focus on earnings
- Francis Halzen wins Nobel Physics Prize for Antarctic 'ghost particle' hunt
Belite Bio Announces Proposed Underwritten Public Offering of American Depositary Shares and Warrants
May 30, 2023 4:01 PM EDTSAN DIEGO, May 30, 2023 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ: BLTE) (Belite Bio or the Company), a clinical stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting retinal degenerative eye diseases which have significant unmet medical needs, today announced that it has commenced an underwritten public offering of American Depositary Shares (ADSs), each representing one of its ordinary shares, and warrants to purchase ordinary shares represented by ADSs. All of the securities in the offering are to be sold by Belite Bio. The offering is subject to market... More



